Opportunities and limitations of SELDI-TOF-MS in biomedical research: Practical advices

Expert Review of Proteomics

Volumn 4, Issue 1, 2007, Pages 51-65

  Poon, Terence C W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bioinformatics; Biomarker; Biomedical research; Biostatistics; Experimental design; Plasma proteome; Protein identification; Proteomics; SELDI TOF MS; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN;

BIOASSAY; DATA MINING; DIAGNOSTIC TEST; MEDICAL RESEARCH; MOLECULAR DYNAMICS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; HUMANS; MASS SPECTROMETRY; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33846934658     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.1.51     Document Type: Review

References (92)

1. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 7, 493-496 (2001).
2. Chaurand P, Caprioli RM. Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis 23, 3125-3135 (2002).
3. Wang MZ, Howard B, Campa MJ et al. Analysis of human serum proteins by liquid phase isoelectric focusing and matrix-assisted laser desorption/ionization-mass spectrometry. Proteomics 3, 1661-1666 (2003).
4. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass. Spectrom. 7, 576-580 (1993). • First report of surface-enhanced laser desorption/ionization (SELDI) time-of-flight (TOF) mass spectrometry (MS) technology.
5. Yeo S, Roh GS, Kim DH et al. Quantitative profiling of plasma peptides in asthmatic mice using liquid chromatography and mass spectrometry. Proteomics 4, 3308-3317 (2004).
6. Wright Jr GL, Cazares LH, Leung SM et al. ProteinChip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis. 2, 264-276 (1999)
7. Melle C, Kaufmann R, Hommann M et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int. J. Oncol. 24, 885-891 (2004).
8. Gretzer MB, Chan DW, van Rootselaar CL et al. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF. Prostate 60, 325-331 (2004).
9. Poon TCW, Chan KCA, Ng PC et al. Serial analysis of plasma proteomic signatures in pediatric patients with severe acute respiratory syndrome and correlation with viral load. Clin. Chem. 50, 1452-1455 (2004).
10. Poon TCW, Yip TT, Chan ATC et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin. Chem. 49, 752-760 (2003).
11. Traum AZ, Wells MP, Aivado M et al. SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions. Proteomics 6, 1676-1680 (2006).
12. Flad T, Bogumil R, Tolson J et al. Detection of dermcidin-derived peptides in sweat by ProteinChip technology. J. Immunol. Methods 270, 53-62 (2002).
13. Coombes KR, Fritsche HA Jr, Clarke C et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin. Chem. 49, 1615-1623 (2003).
14. Tomosugi N, Kitagawa K, Takahashi N et al. Diagnostic potential of tear proteomic patterns in Sjogren's syndrome. J. Proteome Res. 4, 820-825 (2005).
15. Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494 (2003).
16. Ruetschi U, Rosen A, Karlsson G et al. Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J. Proteome Res. 4, 2236-2242 (2005).
17. Gravett MG, Novy MJ, Rosenfeld RG et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 292, 462-469 (2004).
18. Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882-5890 (2004). •• Important article reporting how ovarian cancer markers were identified using a multicenter approach.
19. Petricoin EF III, Ardekani AM, Hitt AB et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002). •• The most crucial article regarding the reproducibility of SELDI-TOF-MS data.
20. Zhukov TA, Johanson RA, Cantor AB et al. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 40, 267-279 (2003).
21. Le L, Chi K, Tyldesley S et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin. Chem. 51, 695-707 (2005).
22. Semmes OJ, Feng Z, Adam BL. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. assessment of platform reproducibility. Clin. Chem. 51, 102-112 (2005). •• Explains how to set-up a set of standard operating procedures to reduce the interlaboratory variations of the SELDI-TOF-MS data.
23. Adam BL, Qu Y, Davis JW et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609-3614 (2002).
24. Li J, Orlandi R, White CN et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 51, 2229-2235 (2005).
25. Li J, Zhang Z, Rosenzweig J et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296-304 (2002).
26. Ebert MP, Meuer J, Wiemer JC et al. Identification of gastric cancer patients by serum protein profiling. J. Proteome Res. 3, 1261-1266 (2004).
27. Poon TCW, Sung JJY, Chow SM et al. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 130, 1858-1864 (2006). •• Demonstrates how to use post-treatment samples to avoid the identification of false-significant diagnostic SELDI peaks owing to systemic bias.
28. Paradis V, Degos F, Dargere D et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41, 40-47 (2005).
29. Semmes OJ, Cazares LH, Ward MD et al. Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia 19, 1229-1238 (2005).
30. Wadsworth JT, Somers KD, Cazares LH et al. Serum protein profiles to identify head and neck cancer. Clin. Cancer Res. 10, 1625-1632 (2004).
31. Agranoff D, Fernandez-Reyes D, Papadopoulos MC et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368, 1012-1021 (2006).
32. Pang RTK, Poon TCW, Chan KCA et al. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin. Chem. 52, 421-429 (2006).
33. Poon TCW, Hui AY, Chan HLY et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin. Chem. 51, 328-335 (2005).
34. Busch A, Michel S, Hoppe C et al. Proteome analysis of maternal serum samples for trisomy 21 pregnancies using ProteinChip arrays and bioinformatics. J. Histochem. Cytochem. 53, 341-343 (2005).
35. Lewczuk P, Esselmann H, Groemer TW et al. Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol. Psychiatry 55, 524-530 (2004).
36. Allard L, Lescuyer P, Burgess J et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 4, 2242-2251 (2004).
37. Poon TCW, Chow SM, Ma BBY et al. Serum proteomic pattern for predicting recurrence of undifferentiated nasopharyngeal carcinoma after radiotherapy - a potential surrogate marker. Clin. Proteomics 1, 365-376 (2004).
38. Goncalves A, Esterni B, Bertucci F et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25, 981-999 (2006).
39. Howell JM, Winstone TL, Coorssen JR, Turner RJ. An evaluation of in vitro protein-protein interaction techniques: assessing contaminating background proteins. Proteomics 6, 2050-2069 (2006).
40. Bane TK, LeBlanc JF, Lee TD, Riggs AD. DNA affinity capture and protein profiling by SELDI-TOF mass spectrometry: effect of DNA methylation. Nucleic Acids Res. 30, E69 (2002).
41. Schweigert FJ, Wirth K, Raila J. Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci. 2, 5 (2004).
42. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20, 777-785 (2004).
43. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl Cancer Inst. 97, 307-309 (2005).
44. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 170 (2002).
45. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96, 353-356 (2004).
46. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol. Cell. Proteomics 3, 367-378 (2004).
47. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin. Cancer Res. 11, 963-965 (2005).
48. Master SR. Diagnostic proteomics: back to basics? Clin. Chem. 51, 1333-1334 (2005).
49. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res. 66, 5540-5441 (2006).
50. Campa MJ, Wang MZ, Howard B et al. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential targets in non-small cell lung cancer. Cancer Res. 63, 1652-1666 (2003).
51. Howard BA, Wang MZ, Campa MJ et al. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 3, 1720-1724 (2003).
52. Lachin J. Introduction to sample size determination and power analysis for clinical trials. Control Clin. Trials 2, 93-113 (1981).
53. Beavis RC, Chait BT. Matrix-assisted laser desorption ionization mass-spectrometry of proteins. Methods Enzymol. 270, 519-551 (1996).
54. Pang RTK, Johnson PJ, Chan CML et al. Technical evaluation of MALDI-TOF mass spectrometry for quantitative proteomic profiling - matrix formulation and application. Clin. Proteomics 1, 295-270 (2004).
55. Quackenbush J. Microarray data normalization and transformation. Nat. Genetics 32(Suppl.), 496-501 (2002).
56. Hubbell E, Liu W-M, Mei R. Robust estimators for expression analysis. Bioinformatics 18, 1585-1592 (2002).
57. Irizarry RA, Bolstad BM, Collin F et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, E15 (2003).
58. Karsan A, Eigl BJ, Flibotte S et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 51, 1525-1528 (2005).
59. Ang IL, Poon TCW, Lai PBS et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma - a glycoproteomic approach. J. Proteome Res. 5, 2691-2700 (2006).
60. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr. Proteomics in early detection of cancer. Clin. Chem. 47, 1901-1911 (2001).
61. Kang X, Xu Y, Wu X et al. Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin. Chem. 51, 56-64 (2005).
62. Zhang X, Lu X, Shi Q et al. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics 7, 197 (2006).
63. Friedman JH, Hastie T, Tibshirani R. Additive logistic regression: a statistical view of boosting. Ann. Stat. 28, 337-407 (2000).
64. Yasui Y. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 4, 449-463 (2003).
65. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001).
66. Xu Y, Selaru FM, Yin J et al. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer. Cancer Res. 62, 3493-3497 (2002).
67. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA 100, 9440-9445 (2003).
68. Banks RE, Stanley AJ, Cairns DA et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 51, 1639-1649 (2005). •• Demonstrates the effects of blood sample processing procedures on the SELDI-TOF-MS data.
69. Yip TTC, Chan JWM, Cho WCS et al. Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin. Chem. 51, 47-55 (2005).
70. Mazzulli T, Low DE, Poutanen SM. Proteomics and severe acute respiratory syndrome (SARS): emerging technology meets emerging pathogen. Clin. Chem. 51, 6-7 (2005).
71. Pang RTK, Poon TCW, Chan KCA et al. Serum amyloid A is not useful in the diagnosis of severe acute respiratory syndrome. Clin. Chem. 52, 1202-1204 (2006). • Demonstrates the importance of appropriate selection of control subjects when discovering biomarkers.
72. Johnson PJ, Williams R. Cirrhosis and the aetiology of hepatocellular carcinoma. J. Hepatol. 4, 140-147 (1987).
73. He QY, Zhu R, Ren Y et al. Serological protein profiling of neuroblastoma by ProteinChip SELDI-TOF technology. J. Cell Biochem. 95, 165-72 (2005).
74. Guo J, Yang ECC, DeSouza L et al. A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. Proteomics 5, 1953-1966 (2005).
75. Ye B, Cramer DW, Skates SJ et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9, 2904-2911 (2003).
76. Malik G, Ward MD, Gupta SK et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 11, 1073-1085 (2005).
77. Cho WC, Yip TT, Yip C et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 10, 43-52 (2004).
78. Le L, Chi K, Tyldesley S et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin. Chem. 51, 695-707 (2005).
79. Wiese R, Belosludtsev Y, Powdrill T, Thompson P, Hogan M. Simultaneous multianalyte ELISA performed on a microarray platform. Clin. Chem. 47, 1451-1457 (2001).
80. Tolson J, Bogumil R, Brunst E et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid α in renal cancer patients. Lab. Invest. 84, 845-856 (2004).
81. Fung ET, Yip TT, Lomas L et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int. J. Cancer 115, 783-789 (2005). • First article to propose the model of response protein amplification cascade to explain the potential application of patterns of high-abundance, host response proteins to diagnosis of diseases.
82. Ahmed N, Barker G, Oliva KT et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br. J. Cancer 91, 129-140 (2004).
83. Kotaka M, Chen GG, Lai PB et al. Analysis of differentially expressed genes in hepatocellular carcinoma with hepatitis C virus by suppression subtractive hybridization. Oncol. Res. 13, 161-167 (2002).
84. Rosty C, Christa L, Kuzdzal S et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 62, 1868-1875 (2002).
85. Anderson NL, Anderson NG. The human plasma proteome. Mol. Cell. Proteomics 1, 845-867 (2002).
86. Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, Steiner S. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 3, 422-432 (2003).
87. Thulasiraman V, Lin S, Gheorghiu L et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 26, 3561-3571 (2005).
88. Guerrier L, Thulasiraman V, Castagna A et al. Reducing protein concentration range of biological samples using solid-phase ligand libraries. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 833, 33-40 (2006).
89. Righetti PG, Boschetti E, Lomas L, Citterio A. Protein equalizer technology: the quest for a "democratic proteome". Proteomics 6, 3980-3992 (2006).
90. Baumann S, Ceglarek U, Fiedler GM et al. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 51, 973-980 (2005).
91. Cheng AJ, Chen LC, Chien KY et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem. 51, 2236-2244 (2005).
92. Villanueva J, Lawlor K, Toledo-Crow R, Tempst P. Automated serum peptide profiling. Nat. Protocols 1, 880-891 (2006).